Cytokines genes polymorphisms in chronic hepatitis C: Impact on susceptibility to infection and response to therapy

Cytokine

Volumn 61, Issue 2, 2013, Pages 478-484

  Pasha, Heba F ^a   Radwan, Mohamed I ^a   Hagrass, Hoda A ^b   Tantawy, Enas A ^a   Emara, Mohamed H ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Cytokines; Hepatitis C; Pegylated interferon; Polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 28B; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DNA EXTRACTION; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALLELES; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-10; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4;

EID: 84873188218     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.11.003     Document Type: Article

References (53)

1. Antaki N., Craxi A., Kamal S., Moucari R., Van der Merwe S., Haffar S., et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010, 30:342-355.
2. Kamal S.M., Hepatitis C. Virus genotype 4 therapy: progress and challenges. Liver Int 2011, 31:45-52.
3. Miller F.D., Abu-Raddad L.J. Evidence of intense ongoing endemic transmission of hepatitis C in Egypt. Proc Natl Acad Sci USA 2010, 107:14757-14762.
4. Dienstag J.L., McHutchison J.G. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 2006, 130:225-230.
5. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 5:21-29.
6. McOmish F., Yap P.L., Dow B.C., Follett E.A., Seed C., Keller A.J., et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994, 32:884-892.
7. Ray S.C., Arthur R.R., Carella A., Bukh J., Thomas D.L. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000, 182:698-707.
8. Al Faleh F.Z., Huraib S., Sbeih F., Al-Karawi M., Al-Rashed R., Al-Mofleh I.A., et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepat 1995, 2:293-296.
9. Shobokshi O.A., Serebour F.E., Skakni L., Al-Saffy Y.H., Ahdal M.N. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999, 58:44-48.
10. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
11. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
12. Bronowicki J.P., Ouzan D., Asselah T., Desmorat H., Zarski J.P., Foucher J., et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006, 131:1040-1048.
13. Derbala M., Amer A., Bener A., Lopez A.C., Omar M., El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005, 12:380-385.
14. Asselah T., Bièche I., Sabbagh A., Bedossa P., Moreau R., Valla D., et al. Gene expression and hepatitis C virus infection. Gut 2009, 58:846-858.
15. Asselah T., Estrabaud E., Bieche I., Lapalus M., De Muynck S., Vidaud M., et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010, 30(9):1259-1269.
16. Nelson D.R., Lauwers G.Y., Lau J.Y.N., Davis G. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon non-responders. Gasteroenterology 2000, 118:655-660.
17. Constantini P.K., Wawrzynowicz-Syczewska M., Clare M., Boron-Kaczmarska A., McFarlane I.G., Cramp M.E., et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002, 22:404-412.
18. Thio C.L., Goedert J.J., Mosbruger T., Vlahov D., S, Strathdee A., et al. An analysis of tumor necrosis factor gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes Immun 2004, 5:294-300.
19. Lio D., Caruso C., Di Stefano R., Colonna Romano G., Ferraro D., Scola L., et al. Almasio; IL-10 and TNF-_ polymorphisms and the recovery from HCV infection. Human Immunol 2003, 64:674-680.
20. Kimura T., Sait T., Yoshimura M., Yixuan S., Baba M., Ji G., et al. Association of transforming growth factor-b1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 2006, 193:1371-1374.
21. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
22. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
23. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
24. Mangia A., Thompson A.J., Santoro R., Piazzolla V., Tillmann H., Patel K., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827.
25. Asselah T., Essioux L., Marcellin P., Fried M.W., Jensen D.M., Germer S., et al. A chromosome 19 SNP (RS12979860) predicts outcome (EVR/SVR) in HCV patients treated with interferon, independent of pegylation or ribavirin. J Hepatol 2010, EASL:A1180.
26. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
27. Khattab M.A., Ferenci P., Hadziyannis S.J., Colombo M., Manns M.P., Almasio P.L., et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011, 54(6):1250-1262.
28. Grünhage F., Nattermann J. Viral hepatitis: human genes that limit infection. Best Practice Res Clin Gastroenterol 2010, 24:709-723.
29. Asselah1 T., De Muynck S., Broët P., Masliah-Planchon J., Blanluet M., Bièche I., et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012, 56:527-532.
30. Falleti E., Bitetto D., Fabris C., Cussigh A., Fornasiere E., Cmet S., et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 2011, 31:891-899.
31. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
32. McCarthy J.J., Li J.H., Thompson A., Suchindran S., Lao X.Q., Patel K., et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138:2307-2314.
33. Montes-Cano M., Garcia-Lozano J., Abad-Molina C., Romero-Gomez M., Barroso N., Aguilar-Reina J., et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
34. Moghaddam A., Melum E., Reinton N., Ring-Larsen H., Verbaan H., Bjro K. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011, 53:746-753.
35. Pereira F.A., Pinheiro da Silva N.N., Rodart I.F., Carmo T.M., Lemaire D.C., Reis M.G. Association of TGF-b1 Codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol 2008, 80:58-64.
36. Vidigal P.G., Germer J.J., Zein N.N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002, 36:271-277.
37. Nattermanna J., Vogela M., Nischalkea H.D., Dantab M., Ahlenstiela G., Michalka M., et al. The transforming growth factor-b high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. Aids 2008, 22:1287-1292.
38. Tambur A.R., Ortegel J.W., Ben-Ari Z., Shabtai E., Klein T., Michowiz R., et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 2001, 71:1475-1480.
39. Barrett S., Coloins M., Kenny C., Ryan E., Keane C.O., Crowe J. Polymorphisms in tumour necrosis factor-α, transforming growth factor-β, interleukin-10, interleukin-6, interferon-_, and outcome of hepatitis C virus infection. J Med Virol 2003, 71:212-218.
40. Yee L.J., Tang J., Herrera J., Kaslow R.A., van Leeuwen D.J. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000, 1:386-390.
41. Rosen Hugo R., Mchutchison John G., Conrad Andrew J., Lentz Jennifer J.J., Gail M., Rose Steven L., et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002, 97:714-720.
42. Dogra G., Chakravarti A., Kar P., Chawla Y. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response. Human Immunol 2011, 72:935-939.
43. Dai C.Y., Chuang W.L., Chang W.Y., Chen S.C., Lee L.P., Hsieh M.Y., et al. Tumor necrosis factor-a promoter polymorphism at position _308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006, 193:98-101.
44. Hohler T., Kruger A., Gerken G., Schneider P.M., Meyer zum Buschenfelde K.H., Rittner C. Tumor necrosis factor alpha promoter polymorphism at position 2238 is associated with chronic active hepatitis C infection. J Med Virol 1998, 54:173-177.
45. Kusumoto K., Uto H., Hayashi K., Takahama Y., Nakao H., Suruki R., et al. Interleukin-10 or tumor necrosis factor-a polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006, 34:24-31.
46. Yu M.L., Dai C.Y., Chiu C.C., Lee L.P., Lin Z.Y., Chen S.C., et al. Tumor necrosis factor _promoter polymorphisms at position - 308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Res 2003, 59:35-40.
47. de Waal Malefyt R. Interleukin-10. Cytokines 1998, 151-167. Academic Press, San Diego. A.R. Mire-Sluis, R. Thorpe (Eds.).
48. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
49. Knapp S., Hennig B.J., Frodsham A.J., Zhang L., Hellier S., Wright M., et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55:362-369.
50. Minton E.J., Smillie D., Smith P., Shipley S., McKendrick M.W., Gleeson D.C., et al. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes. Hum Immunol 2005, 66:127-132.
51. Bahr M.J., el Menuawy M., Boeker K.H., Musholt P.B., Manns M.P., Lichtinghagen R. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003, 23:420-425.
52. Donaldson P.T., Clare M., Constantini P.K., Hadzic N., Mieli-Vergani G., Howard E., et al. HLA and cytokine gene polymorphisms in biliary atresia. Liver 2002, 22(3):213-219.
53. Chuang J.Y., Yang S.S., Lu Y.T., Hsieh Y.Y., Chen C.Y., Chang S.C., et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009, 41:424-430.